<DOC>
	<DOCNO>NCT02592980</DOCNO>
	<brief_summary>Background : Time therapeutic range ( TTR ) measurement quality warfarin therapy low TTR value ( &lt; 50 % ) associate great risk thromboembolic bleed event . Recently , investigator develop pharmacogenetic-based warfarin dose algorithm specifically calibrate Brazilian patient sample . The newly develop algorithm show accurate individual Brazilian population algorithm develop international sample . The aim study : evaluate impact genetic-based algorithm , compare traditional anticoagulation , time achieve therapeutic target TTR percentage ; assess cost-effectiveness genotype-guided warfarin dose specific cohort patient low TTR ( &lt; 50 % ) tertiary cardiovascular hospital . Methods/Design : The investigator recruit 300 patient TTR &lt; 50 % base last three INR value . At first consultation , patient randomize two group : TA ( Traditional Anticoagulation ) group PA ( Pharmacogenetic Anticoagulation ) group . For first group , physician adjust dose accord current INR value , second group , pharmacogenetic algorithm use . At second , third , fourth fifth consultation ( interval 7 day ) INR measure , necessary , dose adjust base guideline . Afterwards , patient INR stable begin measure INR 30 day interval ; patient´s INR stable , patient return 7 day new measurement INR . The main outcome time achieve therapeutic target percentage TTR 4 12 week . In addition , secondary end-point , pharmacoeconomic analysis carry . Discussion : With sample size 150 patient arm separately , study power 93 % observe difference 10 % TTR mean TA PA group . This randomized study include patient low TTR evaluate whether population-specific genetic algorithm might effective traditional anticoagulation select group poorly anticoagulated patient .</brief_summary>
	<brief_title>Evaluation Pharmacogenetic-based Warfarin Dosing Algorithm Patients</brief_title>
	<detailed_description>Investigators recruit 300 patient low TTR ( &lt; 50 % ) Heart Institute- Clinical Hospital- University São Paulo Medical School ( InCor- HCFMUSP ) . The patient randomize two group : Traditional Anticoagulation ( TA ) group Pharmacogenetic Anticoagulation ( PA ) group . The study protocol approve Ethics Committee Medical Research Human Beings Clinical Hospital University São Paulo Medical School ( SDC 4033/14/013 ) . Signed informed consent obtain participant . Only patient atrial fibrillation , 18 year , TTR &lt; 50 % base last three value INR include study . Patients include reach stable dose warfarin , liver dysfunction , alcoholism , use another anticoagulant , use chemotherapy , meet inclusion criterion .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Only patient atrial fibrillation , 18 year , TTR &lt; 50 % base last three value INR include study . Patients include reach stable dose warfarin , liver dysfunction , alcoholism , use another anticoagulant , use chemotherapy , meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>